Table 7.
Distribution of vitamin D status among patients in the JIA group as a function of the therapy used.
| Therapy | 25(OH)D, n (%) | P-value | ||
|---|---|---|---|---|
| <20 ng/mL | 21–29 ng/mL | >30 ng/mL | ||
| 1 | 2 | 3 | ||
| Methotrexate, n = 119 | 46 (38.7%) | 32 (25.9%) | 41 (34.5%) | p1 = 0.75 p2 = 0.56 p3 =0.82 |
| Without methotrexate, n = 31 | 11 (35.5%) | 10 (32.3%) | 10 (32.3%) | |
| Sulfasalazine, n = 37 | 12 (32.4%) | 12 (32.4%) | 13 (35.1%) | p1 = 0.42 p2 = 0.49 p3 =0.87 |
| Without sulfasalazine, n = 113 | 45 (39.8%) | 30 (26.5%) | 38 (33.6%) | |
| Biological preparations, n = 51 | 22 (43.1%) | 16 (31.4%) | 13 (25.5%) | p1 = 0.36 p2 = 0.51 p3 =0.12 |
| Without biological preparations, n = 99 |
35 (35.4%) | 26 (26.3%) | 38 (38.4%) | |
| Systemic glucocorticoids, n = 24 | 9 (37.5%) | 8 (33.3%) | 7 (29.2%) | p1 = 0.98 p2 = 0.53 p3 =0.59 |
| Without systemic glucocorticoids, n = 126 |
48 (38.1%) | 34 (27.0%) | 44 (34.9%) | |
| NSAIP, n = 50 | 21 (42.0%) | 15 (30.0%) | 14 (28.0%) | p1 = 0.75 p2 = 0.56 p3 =0.82 |
| Without NSAIP, n = 100 | 36 (36.0%) | 27 (27.0%) | 37 (37.0%) | |
| Total vitamin D intake (vitamin D preparations and vitamin D together with calcium), n = 89 | 29 (32.6%) | 26 (29.2%) | 34 (38.2%) |
*p1 = 0.10 *p2 = 0.69 *p3 =0.19 |
| Vitamin D preparations, n = 26 | 6 (23.1%) | 6 (23.1%) | 14 (53.8%) |
*p1
=
0.04 *p2 = 0.76 *p3 =0.02 |
| Vitamin D together with calcium, n = 63 |
23 (36.5%) | 20 (31.7%) | 20 (31.7%) |
*p1 = 0.29 *p2 = 0.50 *p3 =0.69 |
| Without vitamin D, n = 61 | 28 (45.9%) | 16 (26.2%) | 17 (27.9%) | - |
*
Compared to patients not receiving vitamin D and calcium supplementation.
JIA, juvenile idiopathic arthritis. Bold values are statistically significant (P < 0.05).